Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03007394 · ClinicalTrials.gov registry record · Phase 2

Lorcaserin in the Treatment of Cocaine Use Disorder

A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 2
Development phase
272
Enrollment target

NCT03007394 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 272 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03007394, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 2
Development phase
272 participants
Enrollment target

Study Summary

The objective of this study is to evaluate the efficacy and safety of lorcaserin in the treatment of cocaine use disorder.

Interventions

  • DRUG Placebo Oral Capsule
  • DRUG Lorcaserin

Trial Details

FieldValue
Enrollment Target 272 participants
Start Date 2017-12-19
Est. Completion 2019-12-01
Phase Phase 2

What the Registry Record Tells You About NCT03007394

The ClinicalTrials.gov registry entry for NCT03007394 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Capsule is the first listed.

NCT03007394 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03007394 about?

NCT03007394 is a clinical study titled "Lorcaserin in the Treatment of Cocaine Use Disorder". The objective of this study is to evaluate the efficacy and safety of lorcaserin in the treatment of cocaine use disorder.

What is the current status of trial NCT03007394?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2017-12-19. Estimated completion is 2019-12-01.

What interventions are being tested in trial NCT03007394?

The interventions under investigation include: Placebo Oral Capsule (DRUG), Lorcaserin (DRUG).

Who is sponsoring clinical trial NCT03007394?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.